Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Anemia in MDS
NCT00030550Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2001
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Thalidomide with Placebo (2 arms). Primary endpoint: Efficacy of thalidomide for the treatment of anemia at 24 weeks. Started Sep 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00030550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030550.